



SNAPSHOT OF STEM CELL AND REGENERATIVE MEDICINE COMPANIES IN AUSTRALIA

9th Edition
2023

INDEX

| | |
|---|-----------|
| Foreword | 4 |
| Making a difference in the Australian regenerative medicine sector | 7 |
| Companies | |
| Australian-based Stem Cell and Regenerative Medicine Companies | |
| Cynata | 10 |
| Mesoblast | 12 |
| Clinical Trials in Australia | 14 |
| Directory of Stem Cell and Regenerative Medicine Companies | 16 |

ABOUT THIS SNAPSHOT

This is the ninth version of the snapshot, which highlights key regenerative medicine companies, largely compiled from information that was publicly available. The information contained within this Snapshot is up-to-date and relevant as of 20th November 2023. The publication was launched online, in conjunction with the Centre for Commercialization of Regenerative Medicine Australia at the NSW Stem Cell Network's 32d workshop; Biomaterials for Regenerative Medicine on November 20, 2023 at Rydges Camperdown.

Disclaimer:

The information contained in the Snapshot of Stem Cell and Regenerative Medicine Companies in Australia: November 2023 is intended solely for general information. This publication must not be relied upon as a substitute for medical, investment or other professional advice. You are encouraged to speak with the relevant contacts provided in the Snapshot for further information. This Snapshot should not be read as reflecting the policies of the NSW Stem Cell Network, its Executive, officers or members. Nor does the Snapshot represent an endorsement of the processes, procedures and technologies described therein. The NSW Stem Cell Network does not accept any liability arising in any way from information contained in this publication, including by reason of negligence for errors or omissions in the information. Only companies that have agreed to be published in the Snapshot were included and, any liability for their content resides with them.



FOREWORD

The NSW Stem Cell Network formed in 2002 as a combined effort from scientists, clinicians, ethicists, legal experts, industry, and community, to campaign for the use of human pluripotent stem cells (hPSC) in research towards cell therapy development for patients in need. The first NSW Stem Cell Network workshop presented the potential of pluripotent stem cells for novel treatments for heart disease, hematopoietic disorders, neurological disorders, and eye disease, as well as legal and ethical perspectives. Over two decades later, these topics are still relevant and hPSC-derived therapies for these indications and many others are in ongoing early phase clinical trials worldwide. There are in fact 127 listed clinical trials from hPSC derived sources globally, as of August 2023.

Until now in Australia, four clinical trials from hPSC-Advanced Therapy Medicinal Product (ATMP)-derived medicines have been initiated:

- 2016: A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease (NCT02452723)
- 2017: A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease (NCT02923375)
- 2020: The MEseNchymal covid-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND) (NCT04537351)
- 2022: Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers (NCT05165628)

Three of these clinical trials are from Cynata Therapeutics, including the 2017 study that was the first study globally to be completed from an induced pluripotent stem cell derived source. This is the only study on the list completed thus far. So two decades of campaigning, four initiated clinical trials by only two entities and only one completed trial – are we getting the best impact from Australian research for patients? Are we failing to translate our research, or is it that we have a lot of research developed through fantastic initiatives like Stem Cells Australia, the National Stem Cell Foundation and The Australian Regenerative Medicine Institute on the cusp of translation but not connected to the competencies needed to translate? I'd suggest the latter is true. This is a global problem in cellular therapies.

Academics are not trained for product development and the competencies needed for it are not part of their normal professional networks. However, the novelty and complexity of cell-based medicines needs the academic to extend themselves further into the product development pathway, not required in the same way for synthetic and recombinant protein pharmaceutical modalities. If we can crack this nut, we open to an avalanche of potential therapies reaching Australian patients.

How to crack the nut? Network building! Take a look at this year's snapshot. How many service providers, quality, manufacture, regulatory, commercialisation experts, big pharma, clinical competencies do you have contact with? Without this network, products will not make it to the market. With three of these competencies, products might make it to first in human clinical trial but will fail in regard to patient access without a well-informed commercial strategy – any company interested in the academic product/trial will need to do the trial again once they change the product to adapt to commercial suitability. Scraping by to save time in getting to the clinic will hinder product development in the next steps. Best to accept 1) the 3 –5 years Good Manufacturing Practice (GMP) adaptation and manufacture takes, and 2) that research protocols are not xeno-free, controlled or defined in the quality and regulatory context required for medicine development. These are their own fields of expertise and by definition current GMP (cGMP) means that standards must be acceptable in the moment, not what would have been two or ten years ago.

Our understanding of what translation is needs to change. Translation is not proof of concept, nor is it safety and mechanism of action in non-good laboratory practice (GLP) models with our non-GMP adapted protocol.

'Real translation' starts when you make contact with the cell and gene therapy village of experts listed above. A concerted funding pool is needed to achieve real translation and the funding bodies need to understand their role in expectation and understanding of what real translation is. The Medical Research Future Fund and Therapeutic Innovations Australia supports are a great start! Now it's time to empower the researchers with the networks they need. The 31st NSW Stem Cell Network workshop attempted to start bringing this network together.

The NSW Stem Cell Network's 31st workshop on "Cell Therapy – Bench to Bedside to Reimbursement" showcased the breadth of Australian experts in this space to see cell therapy not only as a research and clinical pursuit, but as an essential commercial pursuit for enabling promised patient access. Speakers represented product developers, analytics providers, contract research, sales, and manufacturing organisations, manufacture facilities, regulatory, dose preparation, process development and automation, regional reimbursement and implementation, national health technology assessment, and negotiation and policy development – a snapshot in itself of the broad competencies in this field. The workshop was well received with general excitement about pulling in those with

expertise that is essential for clinical translation, who are often left out from more data based scientific programs. Scientific programs must continue, but let's consider what is needed in addition to them.

This year's Snapshot attempts to showcase stakeholders involved in the development of 'Advanced Medicines', in-vivo gene therapies, ex-vivo gene/cell therapies, or cell therapies. There are currently six of this type of product approved in Australia: Zolgensma, Luxtura, Kymriah, Yescarta, Tecartus, Carvykti and Australian 'grown' Ortho-ACI. The Snapshot attempts to expose the reader to the substantial network of expertise and support that is available in Australia for the development of pluripotent derived medicines and to kickstart strengthening of this network with a focus on product development systems and processes.

If your initiative is missing from this year's Snapshot, please contact the NSW Stem Cell Network to make sure you are included next year! Network building to drive patient access was the principle on which the NSW Stem Cell Network was founded and it continues in this important role today.

Dr Heather Main

Founder, HOYA

Consulting Project Manager, ATMP Sweden

Organiser of the 18th, 19th and 31st

NSW Stem Cell Network workshops

For more information, please contact:

Deb Rooz

Manager, NSW Stem Cell Network

Phone: (02) 9552 9982

Email: stemcellmanager@stemcellnetwork.org.au

MAKING A DIFFERENCE IN THE AUSTRALIAN REGENERATIVE MEDICINE SECTOR



'The project will establish CCRM Australia, an Australian hub of Canada's Commercialisation Centre for Regenerative Medicine (CCRM). As an Australian not-for-profit organisation, CCRM Australia will support the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies, with a national focus'. That was the project description of CCRM Australia's first grant application to establish itself as an entity, and it has been at the core of many CCRM Australia activities. From programs that encouraged local industry-academia collaboration, training and mentorship, to attracting international investment and activities into Australia, the goals were always the same. CCRM Australia sought to increase the pipeline of commercial activities and workforce development, regardless of where those activities took place.

A pivotal moment occurred when Ausbiotech and CCRM Australia, with the leadership of Dr Tim Oldman and support from Brent McPherson from World Courier, mooted the idea of creating a forward-looking strategy document for the Australian Regenerative Medicine Sector. Despite the history and numerous achievements made by Australia such as the Australian Stem Cell Centre, Stem Cells Australia, Australian Regenerative Medicine Institute as well as associations like the NSW Stem Cell Network; there was not a lot of available information regarding the state of the industry and how competitive is Australia relative to the rest of the world. MTPConnect eventually funded the concept and CCRM Australia actively provided input during the research phase including the creation and management of the survey, which led to the seminal "Regenerative Medicine, Opportunities for Australia" report in 2018. This report was the first to provide a comprehensive assessment of the Australian regenerative medicine sector and recommendations needed to improve the competitiveness of the Australian sector for it to compete effectively on the world stage. The key recommendations were workforce and talent development, attracting private investment, building manufacturing capability, and fostering more collaborations between industry and academia. The report also made the case for a catalyst body that would advocate on behalf of the industry in areas of regulatory reform and policies that align with best practices and harmonisation amongst the major markets.

2023

The 2018 MTPConnect Opportunities report set in motion a number of major initiatives and documents that aimed at benchmarking and reinforcing the recommendations to enhance Australia's competitive position. CCRM Australia remained committed to its national focus in assisting local biotechnology companies and researchers to translate and commercialise their regenerative medicine inventions. An example is the upcoming CRC round in December 2023, which aims to build biomanufacturing capabilities, workforce development and training programs that impart research and development, entrepreneurial and technical (GMP manufacturing) skills/capabilities. The Solutions for Manufacturing Advanced Regenerative Therapies (SMART) Cooperative Research Centre led by CCRM Australia and to be hosted by the University of Queensland will consist of industry-academia projects that overcome challenges along the commercialisation value chain at the process development, preclinical, and clinical stages. The SMART CRC will leave a legacy of platform technologies in areas including bioseparation, assay development, biomanufacturing, etc. that will support the existing and future Australian biotechnology companies. Having local solutions available helps create a pipeline of local startups because there is less need to explore other jurisdictions such as the United States for solutions. The aims and legacy of the SMART CRC are evident of decisions and strategies being informed by the 2018 MTPConnect report as well as the more recent National Cell and Gene Therapy Manufacturing Blueprint.

In the previous edition of NSW Snapshot in 2022, we spoke about the CCRM Global Network of hubs that extends out from its origin in Canada to Australia and the Netherlands. A global network of hubs facilitates access to cutting-edge technologies, production facilities, different markets, and a virtual team of experts that can be called upon to problem-solve and innovate.

CCRM Australia would like to extend its congratulations to the creation of CCRM Nordic and its inaugural CEO Fredrik Wessberg. We look forward to future engagements and collaborations as hubs work towards building a global network that will play a critical role in enabling the commercialisation and diffusion of regenerative medicine therapies around the world. Lastly, CCRM Australia would like to congratulate the NSW Stem Cell Network on the 2023 Snapshot. We applaud the continuous commitment of the NSW Stem Cell Network to educate and foster collaborations that drive the realisation and adoption of stem cell therapies. It is a privilege for CCRM Australia to be part of the 9th Edition Snapshot of Stem Cell and Regenerative Medicine Companies in Australia and we look to continue our support in future issues.

Silvio Tiziani

Chief Executive Officer
CCRM Australia Ltd



AUSTRALIAN-BASED COMPANIES

Cynata Therapeutics Ltd is a clinical stage biotechnology company developing a proprietary therapeutic platform technology, known as Cymerus™. The platform is based on discoveries made at the University of Wisconsin-Madison, a world leader in stem cell research. Cymerus addresses a critical shortcoming in existing methods of production of allogeneic mesenchymal stem cells (MSCs) for therapeutic use: the ability to achieve consistent economic manufacture at commercial scale without reliance upon multiple donors. There is extensive interest in the development of MSCs as therapeutic agents, in light of their ability to secrete bioactive molecules such as cytokines, chemokines, and growth factors, in addition to their immunosuppressive and immunoregulatory properties. There are currently over 1000 clinical trials of MSCs, covering an extremely wide range of therapeutic indications, including haematological, cardiovascular, orthopaedic, gastrointestinal, and autoimmune disorders, among others. However, there are very major limitations in conventional methods of MSC production including the dependence upon multiple donors, the variability between donors, the relative scarcity of MSCs in adult tissue, and the low proliferative capacity of adult stem cells compared to pluripotent stem cells. Cynata believes that the Cymerus technology addresses these issues, uniquely placing Cynata to capitalise on the flourishing field of stem cell therapeutics. The Company has been covered in highly favourable equity research analyses published by Baillieu Holst, BBY, SeeThru Equity, H.C. Wainwright, Shaw & Partners, and MST Access. Cynata's first therapeutic product CYP-001 has shown highly promising efficacy in a Phase 1 clinical trial in acute graft-versus-host disease (aGvHD). This has enabled the Company to initiate multiple further clinical trials. Cynata has a strategic partnership with FUJIFILM, a major participant in the regenerative medicine sector and the third largest shareholder in Cynata, behind Fidelity and BioScience Managers, with around 6% of the shares.

PRODUCT PIPELINE

Cynata is the world leader in developing iPSC-derived cell therapy products. Following excellent results in a Phase 1 clinical study in a GvHD, the Company filed an IND application with the US FDA and secured clearance of that IND in 2022, enabling trial start-up activities to commence on a potential Phase 2 clinical trial in aGvHD. A phase 3 clinical trial commenced in 2020 in osteoarthritis in association with the University of Sydney while a clinical trial in diabetic foot ulcers commenced in 2021. A clinical trial in patients with severe respiratory complications, such as have been seen in COVID-19, patients, commenced in 2020. However this trial concluded in 2022 due to ongoing recruitment challenges. The Phase 1 clinical trial results in aGvHD, which have been the subject of a front-page article in Nature Medicine, provide a sound foundation for further development in numerous other indications, such as those in which MSCs from other sources have previously been investigated. Cynata has also reported clear efficacy in pre-clinical proof-of-concept studies with its Cymerus MSC products in models of cytokine release syndrome (CRS), CLI, diabetic wounds, myocardial infarction, asthma, idiopathic pulmonary fibrosis, sepsis, acute respiratory distress syndrome (ARDS) and in GvHD. Cynata is pursuing a vigorous partnering agenda in order to fully exploit its outstanding cell therapy platform.

LATEST NEWS

Active recruitment has continued in the osteoarthritis and diabetic foot ulcer trials. The long-standing relationship with FUJIFILM was strengthened with the establishment of a new strategic partnership involving manufacturing services to ensure long term supply of Cynata's proprietary Cymerus MSC products. Cynata has successfully achieved IND clearance from the US FDA for a proposed Phase 2 clinical trial in aGvHD. Additionally, the Company's intellectual property portfolio has advanced with the grant of patents in multiple jurisdictions, including the USA.



CEO: Dr Kilian Kelly

Established in Australia in 2011

ABN: 98 104 037 372

Status: PUBLIC (ASX:CYP)

www.cynata.com


CONTACT

Dr Kilian Kelly

E: kilian.kelly@cynata.com

cynata

therapeutics





Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.

The Company's portfolio of Phase 3 product candidates comprises RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), remestemcel-L for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. Mesoblast also has a promising emerging pipeline of product candidates and next generation technologies.

Innovative technology platform enables scalable manufacturing

Mesoblast's novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.

Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast's cells is they can be administered to patients without the need for donor-recipient matching or recipient immune suppression.

Mesoblast has proprietary technology that facilitates the increase in yields necessary for the long-term commercial supply of its product candidates, and next generation manufacturing processes using xeno-free technologies and three-dimensional bioreactors to reduce labour, drive down cost of goods and improve manufacturing efficiencies.

Robust Intellectual Property Estate

Mesoblast has an extensive patent portfolio with over 1,100 patents and patent applications across 82 patent families, and patent terms extending through 2040. These patents cover composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells, and provide strong commercial protection for our products in all major markets, including the United States, Europe, Japan and China. Licensing agreements with JCR, Grünenthal, Tasly and Takeda highlight the strength of Mesoblast's extensive intellectual property portfolio covering mesenchymal lineage cells.

Mesoblast will continue to use its patents to prosecute its commercial rights as they relate to its core strategic product portfolio. When consistent with the Company's strategic objectives, it may consider providing third parties with commercial access to its patent portfolio.

Evidence-based Science and Translational Medicine

Mesoblast's approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. These safeguards are intended to ensure the integrity and reproducibility of results, and to ensure that outcomes observed are scientifically reliable.

Global Operations

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).



Chief Executive: Dr. Silviu Itescu

Established in Australia 2004

ABN: 68 109 431 870

Status: Public

www.mesoblast.com

info@mesoblast.com



Mesoblast Limited is a global leader in cellular medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.



CLINICAL TRIALS IN AUSTRALIA

CLINICAL TRIALS

In September 2021, the Regenerative Medicines Catalyst Programme released an up-to-date and extensive overview of Australia's Regenerative Medicine Clinical Trials Database, which can be viewed here. Read more about the report [here](#).



COMPANY DIRECTORY

DIRECTORY

COMPANIES DEVELOPING ADVANCED MEDICINES

| Company | Website | Location |
|--|-------------------------|----------|
| Algorae Pharmaceuticals (formerly Living Cell Technologies) | algoraepharma.com | VIC |
| BioOra | bioora.com | NZ |
| Cancure | cancure.com | QLD |
| Carina Biotech | carinabiotech.com | SA |
| Cartherics | cartherics.com | VIC |
| Celosia Therapeutics | celosiatx.com | NSW |
| CSL | csl.com.au | VIC |
| Currus Biologics | currusbio.com | VIC |
| Cynata | cynata.com | VIC |
| HaemaLogiX Pty Ltd | haemalogix.com | NSW |
| Imugene Ltd | imugene.com | NSW |
| Mesoblast | mesoblast.com | VIC |
| Orthocell | orthocell.com | WA |
| Prescient Therapeutics | ptxtherapeutics.com | VIC |
| PYC Therapeutics | pyctx.com | WA |
| Regeneus | regeneus.com.au | NSW |
| Skin2Neuron | skin2neuron.org | NSW |
| Tessara Therapeutics | tessaratherapeutics.com | VIC |

DIRECTORY

TGA LICENSED GMP FACILITIES (AND PROCESS DEVELOPMENT)

| Company | Website | Location |
|---|--|----------|
| Biocina | biocina.com | SA |
| Biovirus (NZ - not TGA) | biovirus.com | NZ |
| Cell & Tissue Therapies Western Australia (CTTWA) | rph.health.wa.gov.au/Services/Cell-and-Tissue-Therapies-WA | WA |
| Cell Therapies Pty Ltd | celltherapies.com.au | VIC |
| CSL Ltd | csl.com | VIC |
| Orthocell | orthocell.com | WA |
| Pantheon by Thermo Fisher | thermofisher.com/au/en/home/brands/patheon.html | QLD |
| Q-Gen Cell Therapies | qimrberghofer.edu.au/commercial-collaborations/partner-with-us/q-gen-cell-therapeutics | QLD |
| Royal Brisbane and Women's | metronorth.health.qld.gov.au/rbwh | QLD |
| Scinogy | scinogy.com | VIC |
| Sydney Cell and Gene Therapy | sydneycellandgenetherapy.org | NSW |

PROCESS DEVELOPMENT-ONLY FACILITIES

| Company | Website | Location |
|---|--|----------|
| Centre for Advanced Therapies (CAT) at Royal Perth Hospital | rph.health.wa.gov.au/Services/Cell-and-Tissue-Therapies-WA | WA |
| Centre of Excellence in Cellular Immunotherapies, Peter Mac | petermac.org/research/research-centres-and-centres-of-excellence/centre-of-excellence-in-cellular-immunotherapy/about-the-centre-excellence-in-cellular-immunotherapy | VIC |
| University of Queensland/CCRM Australia | ccrmaustralia.com.au/news/advanced-cell-therapy-manufacturing-initiative-to-be-established-in-brisbane | QLD |

DIRECTORY

NON TGA LICENSED PHASE 0/1 MANUFACTURE FACILITIES

| Company | Website | Location |
|---|---|----------|
| Cell & Molecular Therapies, Royal Prince Alfred Hospital | slhd.health.nsw.gov.au/rpa-hospital-research/cell-molecular-therapies | NSW |
| Hudson Institute Cell Therapy and Regenerative Medicine Platform (Hudson Institute) | hudson.org.au/facilities/ | VIC |
| Magellan Stem Cells | magellanstemcells.com.au | VIC |
| Westmead Viral Vector Manufacturing Facility, Westmead Health Precinct | westmeadhealthprecinct.com | NSW |

ADVANCED MEDICINE TOOLS PROVIDERS

| Company | Website | Location |
|----------------------------|--|----------|
| Biomerieux | biomerieux.com | NSW |
| Biorad | bio-rad.com | NSW |
| Celleo | celleo.com | VIC |
| Charles River Laboratories | .criver.com/microbial-solutions-facility-melbourne-australia | VIC |
| Culturon | culturon.com.au | NSW |
| Cytiva | cytivalifesciences.com | NSW |
| Decode Science Pty Ltd | decodescience.com.au | VIC |
| Eppendorf | eppendorf.com | NSW |
| GenScript | genscript.com | N/A |
| In Vitro Technologies | invitro.com.au | NSW |
| Inventia Life Science | inventia.life | NSW |
| Invetech | invetechgroup.com | VIC |
| Lonza | lonzaboisience.com.au | NSW |
| Merck Group | sigmaaldrich.com | NSW |
| Messenger Bio | messenger.bio | VIC |
| Miltenyi Biotec | miltenyi.com | NSW |
| Sartorius | sartorius.com/en | VIC |
| Scientifix Pty. Ltd. | scientific.com.au | VIC |
| Scinogy | scinogy.com | VIC |
| Stemcell Technologies | stemcell.com | VIC |
| Terumo BCT | terumobct.com | NSW |
| ThermoFisher | thermofisher.com.au | NSW |

DIRECTORY

ADVANCED MEDICINE CRO/CSO

| Company | Website | Location |
|---------------------------------|--|----------|
| CryoPDP | cryopdp.com | NSW |
| Eurofins | eurofins.com.au | NSW |
| IQVIA | iqvia.com | NSW |
| Phenomics Australia | phenomicsaustralia.org.au | ACT |
| World Courier AmerisourceBergen | worldcourier.com | NSW |

ADVANCED MEDICINE CONSULTING SERVICES

| Company | Website | Location |
|---|--|----------|
| Alithia Life Sciences | alithialifesciences.com | VIC |
| Asia Pacific Consultants Pty. Ltd. | a-p-c.com.au/services/gmp-and-quality-systems | NSW |
| Biointelect Pty Ltd | biointelect.com | NSW |
| Centre for Biopharmaceutical Excellence | cbe-ap.com.au | VIC |
| Increment4 Pty. Ltd. | increment4.com | VIC |
| ProPharma Group | propharmagroup.com | VIC |

COMMERCIAL PROVIDERS OF ADVANCED MEDICINES

| Company | Website | Location |
|--|--|----------|
| Gilead Science | gilead.com.au | NSW |
| Janssen-Cilag | janssen.com/australia | NSW |
| Novartis Pharmaceuticals Australia Pty Ltd | novartis.com/au-en | NSW |
| Orthocell | orthocell.com | WA |

DIRECTORY

INSTITUTIONS TREATING PATIENTS WITH CGT PHARMACEUTICALS

| Company | Website | Location |
|---|--|----------|
| Alfred Health Victoria | alfredhealth.org.au | VIC |
| Australasian Leukaemia and Lymphoma Group | allg.org.au | VIC |
| Chris O'Brian Lifehouse | mylifehouse.org.au | NSW |
| Fiona Stanley Hospital | fsfhg.health.wa.gov.au | WA |
| Monash Health | monashhealth.org | VIC |
| Murdoch Children's Research Institute | mcri.edu.au | VIC |
| Peter MacCallum Cancer Centre | petermac.org | VIC |
| QIMR Berghofer Medical Research Institute | qimrberghofer.edu.au | QLD |
| Royal Perth Hospital | rph.health.wa.gov.au | WA |
| Sir Charles Gairdner Hospital | scgh.health.wa.gov.au | WA |
| St. Vincent's Hospital Sydney | svhs.org.au | NSW |
| Western Sydney Local Health District | wslhd.health.nsw.gov.au | NSW |
| Westmead Hospital/Western Sydney LHD | wslhd.health.nsw.gov.au/Westmead-Hospital | NSW |

NON TGA AUTOLOGOUS MESENCHYMAL TRANSPLANT

| Company | Website | Location |
|------------------|--|----------|
| Magellan | magellanstemcells.com.au | VIC |
| Cell Innovations | cell-innovations.com.au | NSW |

DIRECTORY

CLINICAL TRIALS OF ADVANCED MEDICINES

| Company | Website | Location |
|------------------------------|--|----------|
| Bayer | bayer.com.au/en | N/A |
| Biogen Inc | biogen.com | N/A |
| BioMarin Pharmaceutical Inc. | biomarin.com | NSW |
| Celgene Corp | celgene.com.au | VIC |
| Cynata Therapeutics Ltd | cynata.com | VIC |
| GlaxoSmithKline | gsk.com/en-gb | NSW |
| Pfizer | pfizer.com.au | NSW |
| Roche | roche-australia.com | NSW |

FUNDING SOURCES

| Company | Website | Location |
|----------------------------------|--|----------|
| Bioscience Managers Pty Ltd | biosciencemanagers.com | VIC |
| Brandon Capital Partners Pty Ltd | brandoncapital.vc | NSW/VIC |
| IP Group Pty Ltd | ipgroupanz.com | NSW |
| Morgans Pty Ltd | morgans.com.au | QLD |
| Medical Research Future Fund | health.gov.au/our-work/medical-research-future-fund | N/A |
| OneVentures Pty Ltd | one-ventures.com.au | NSW |

DIRECTORY

RESEARCH FACILITIES

| Company | Website | Location |
|---|---|----------|
| Australian Regenerative Medicine Institute | armi.org.au | VIC |
| Bond University | bond.edu.au | QLD |
| Charles Darwin University | cdu.edu.au | NT |
| Children's Medical Research Institute | cmrijeansforgenes.org.au | NSW |
| Curtin University | curtin.edu.au | WA |
| Edith Cowan University | ecu.edu.auresearch | WA |
| Flinders University | flinders.edu.au | SA |
| Florey Institute of Neuroscience | florey.edu.au | VIC |
| Garvan Institute of Medical Research | garvan.org.au | NSW |
| Harry Perkins Research institute | perkins.org.au | WA |
| James Cook University | jcu.edu.au | QLD |
| Lions Eye Institute | lei.org.au | WA |
| Macquarie University | mq.edu.au | NSW |
| Monash University | monash.edu | VIC |
| Murdoch Children's Research Institute (MCRI) | mcri.edu.au | VIC |
| Murdoch University | murdoch.edu.au | WA |
| QIMR Berghofer Medical Research Institute, Q-Gen Cell Therapeutics | qimrberghofer.edu.aucommercial-collaborations/partner-with-us/q-gen-cell-therapeutics | QLD |
| Queensland Immunology Research Centre | qirc.com.au | QLD |
| Queensland University of Technology | qut.edu.au | QLD |
| ReNEW at MCRI | mcri-renew.org.auabout | VIC |
| Telethon Kids Institute | telethonkids.org.au | WA |
| Translational Research Facility of the Monash Health Translation Precinct | mhtp.org.au | VIC |
| University of Adelaide | adelaide.edu.au | SA |
| University of Melbourne | unimelb.edu.au | VIC |
| University of NSW | unsw.edu.au | NSW |
| University of Queensland | uq.edu.au | QLD |
| University of South Australia | unisa.edu.au | SA |
| University of Sydney | sydney.edu.au | NSW |
| University of Tasmania | utas.edu.au | TAS |
| University of Technology Sydney | uts.edu.au | NSW |
| University of Western Australia | uwa.edu.au | WA |
| University of Wollongong | uow.edu.au | NSW |

DIRECTORY

OTHER RM PRODUCT DEVELOPERS

| Company | Website | Location |
|----------------------|--|----------|
| Anteris Technologies | anteristech.com/home.html | WA |
| Anatomics Pty Ltd | anatomics.com | VIC |
| Avita Medical | avitamedical.com | VIC |
| Osteopore | osteopore.com | WA |
| Polynovo Ltd | au.polynovo.com | VIC |
| ReNerve | renerve.com.au | VIC |
| Vivazome | vivazome.com | VIC |

CELL AND TISSUE REPOSITORIES

| Company | Website | Location |
|------------------------|--|-------------|
| BDMI Cord Blood Bank | parentsguidecordblood.org/en/banks/bmdi-cord-blood-bank | VIC/NSW/QLD |
| Cell Care | cellcare.com.au | VIC |
| Cryosite Ltd | cryosite.com | VIC |
| NSW Statewide Biobank | biobank.health.nsw.gov.au | NSW |
| Sydney Cord Blood Bank | schn.health.nsw.gov.au/find-a-service/health-medical-services/sydney-cord-blood-bank | NSW |

DIRECTORY

SUPPORTING INITIATIVES

| Company | Website | Location |
|--|--|-----------|
| ARCS Australia Ltd. | arcs.com.au | NSW |
| Australasian Society for Stem Cell Research | asscr.org | N/A |
| Australasian Gene and Cell Therapy Society | agcts.org.au | N/A |
| Australian Red Cross Lifeblood | lifeblood.com.au | NSW |
| Australia's Industry Growth Centre | industry.gov.au/science-technology-and-innovation/industry-innovation/industry-growth-centres | ACT |
| BioCurate | biocurate.com | VIC |
| Centre for Commercialisation of Regenerative Medicine Australia | ccrmaustralia.com.au | VIC |
| Cell and Gene Therapy Catalyst | ausbiotech.org/programs/australias-cell-and-gene-catalyst | N/A |
| Cerebral Palsy Alliance | cerebralpalsy.org.au | NSW |
| CSIRO | csiro.au/en | ACT / NSW |
| Foundation for the Accreditation of Cellular Therapies | factglobal.org | N/A |
| International Society for Cell Therapy Australia and New Zealand (ANZ) | isctglobal.org/about/about-us | N/A |
| Jumar Bioincubator | jumarbio.com | VIC |
| Medicines Australia | medicinesaustralia.com.au | ACT |
| MTP Connect/ REDI | mtpconnect.org.au/programs/REDI | N/A |
| NSW Stem Cell Network | stemcellnetwork.org.au | NSW |
| Therapeutic Innovations Australia | therapeuticinnovation.com.au | Australia |

